Tinnitus Treatment Report

www.TinnitusTreatmentReport.com

Susan Shore

Susan Shore’s New “Auricle Device” for Tinnitus Is Almost Ready for Commercial Release…

The breakthrough device — based on 20 years of Shore’s research and $14 million in funding — is “nearly market ready,” according to Auricle Inc CEO and Co-Founder, Jon Pearson.

Auricle tinnitus logo
Logo for Susan Shore’s new medical device startup: Auricle Inc.

Here is the official product description (Auricle Inc):

Device that combines auditory frequencies and timed somatosensory stimuli to suppress tinnitus-generating neurons that cause ringing in the ears.

Here are the latest details — developing story:

  • Susan Shore recently co-founded a company called Auricle Inc.
  • Auricle Inc is a medical device venture (startup) created to commercialize Shore’s tinnitus device and patents.
  • The company was formed with the approval of the University of Michigan Reagents and there is an “Option Agreement” between the university and Auricle Inc.
  • The domain name for Auricle Inc (www.auricleinc.com) is registered and associated with the company. No website has been created yet (as of September 7, 2021, 1:28pm EST).

Excerpt from the agreement:

“… a for-profit company called Auricle Inc. (the “Company”). The Company was formed recently to commercialize a device to treat tinnitus…”

Susan Shore, PhD, a Professor in the Department of Otolaryngology-Head and Neck Surgery, and David Martel, Graduate Student Research Assistant in the Department of Otolaryngology-Head and Neck Surgery, are partial owners of a for-profit company called Auricle Inc. (the “Company”). The Company was formed recently to commercialize a device to treat tinnitus and desires to option from the University of Michigan the University’s rights associated with the following technology:

UM OTT File No. 5507, entitled: “Tailored Auditory – Somatosensory Stimulation to Treat Tinnitus” (Inventors: Seth Koehler, David Martel, Susan Shore)

The Office of Technology Transfer selected the Company as a University partner and negotiated the terms of the proposed Agreement in accordance with University policy and its accepted licensing principles.

Here is the Gen 2.0 clinical unit (i.e., the one that was used in the latest Shore clinical trial, it would seem)… which might give us some idea of the Auricle device product hardware (note: no confirmation yet on what the market-ready device will look like).

Auricle device demo product by Susan Shore

In addition…

Billy Mays Susan Shore Meme

Video: 2-Minute Auricle Inc Tinnitus Device Investor Pitch

The unlisted video, “Auricle 2 min 2021 Rosenman Innovator Demo Day AU I0F2VG4”, only has 45 views at the time of this writing (September 7, 2021, 1:29pm EST). Also worth mentioning are the social signals: the video currently has one Like and one comment… both of which can be traced to a mysterious “Michael Sutton” character. Hmmmm…

This is a developing story. Expect more updates soon. Sources below. Remember to subscribe. And please share, if you want to encourage more “exclusive” updates like this one.

More to follow…

“No official release date yet. As soon as I know more, I will email the list.”
– Michael

Get Email Updates

Subscribe to the Tinnitus Treatment Report email newsletter to stay informed about the release date for Susan Shore’s Auricle Device for tinnitus. Plus, other promising new tinnitus treatments on the horizon. It’s free, you get one or two emails per week (but only when something interesting is happening). No sneaky third party emails. Privacy respected. Unsubscribe any time with one click.

References

  • https://techtransfer.umich.edu/companies/auricle-inc/
  • https://innovation.medicine.umich.edu/portfolio_post/shore/
  • https://rosenmaninstitute.org/portfolio/auricle/
  • more sources will be added as this article is expanded

Cochlear nucleus small cells use olivocochlear collaterals to encode sounds in noise [Preprint] [Susan Shore]

https://www.biorxiv.org/content/10.1101/2021.05.20.444983v1

https://www.biorxiv.org/content/10.1101/2021.05.20.444983v1.full.pdf

Cochlear nucleus small cells use olivocochlear collaterals to encode sounds in noise
Adam Hockley, Calvin Wu, Susan E Shore
doi: https://doi.org/10.1101/2021.05.20.444983

Abstract
Understanding speech, especially in noisy environments, is crucial to social interactions. Yet, as we age, speech processing can be disrupted by cochlear damage and the subsequent auditory nerve fiber degeneration. The most vulnerable-medium and high-threshold-auditory nerve fibers innervate various cell types in the cochlear nucleus, among which, the small cells are unique in receiving this input exclusively. Here, we characterize small cell firing characteristics, demonstrating superior temporal as well as intensity coding. We show that small-cell unique coding properties are facilitated by direct cholinergic input from the medial olivocochlear system. These results highlight the small cell-olivocochlear circuit as a key player in signal processing in noisy environments, which may be selectively degraded in aging or after noise insult.

Pre-emptive MOC-pathway enhancement protects the cochlea from synaptopathic acoustic
304 trauma (Boero et al., 2018), but whether increased MOC activation following synaptopathic noise
305 exposure could reverse speech-in-noise deficits is still unknown. Conversely, in humans with
306 tinnitus or hyperacusis, an increased contralateral suppression of otoacoustic emissions
307 (Knudson et al., 2014) suggests an over-responsive MOC system in this pathology. MOC neurons
308 are modulated by descending input from the inferior colliculus (Malmierca et al., 1996; Robertson
309 & Mulders, 2000; Schofield & Cant, 1999), auditory cortex (Coomes & Schofield, 2004; Mulders
310 & Robertson, 2000), and local inhibitory interneurons of the medial nucleus of the trapezoid body
311 (Torres Cadenas et al., 2020). Descending modulation may be a route for auditory attention to
312 affect peripheral processing, which may explain attentional facilitation of speech-in-noise
313 understanding (de Boer et al., 2012). Descending modulation of MOC activity would also affect
available under aCC-BY-NC-ND 4.0 International license.
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
bioRxiv preprint doi: https://doi.org/10.1101/2021.05.20.444983; this version posted May 21, 2021. The copyright holder for this preprint (which
13
314 MOC collateral input to CN SCs, which accurately encode intensity, providing an additional action
315 pathway for auditory attention. The SCC in humans occupies a larger proportion of the CN than
316 in rodents, and is therefore poised to play a major role in central mechanisms of speech
317 perception (Moore & Osen, 1979).

Back to top